USA flag logo/image

An Official Website of the United States Government

NEW GADOLINIUM-BORON COMPOUNDS FOR NEUTRON CAPTURE THERAPY

Award Information

Agency:
Department of Energy
Branch:
N/A
Award ID:
17502
Program Year/Program:
1993 / SBIR
Agency Tracking Number:
17502
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BORON BIOLOGICALS, INC.
620 HUTTON ST, STE 104 RALEIGH, NC 27606
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1993
Title: NEW GADOLINIUM-BORON COMPOUNDS FOR NEUTRON CAPTURE THERAPY
Agency: DOE
Contract: N/A
Award Amount: $500,000.00
 

Abstract:

NEUTRON CAPTURE THERAPY IS A VERY PROMISING THERAPY FOR CERTAIN TUMORS, SUCH AS GLIOMAS AND MELANOMAS. SEVERAL NUCLEI HAVE HIGH CROSS SECTIONS FOR THERMAL NEUTRONS, OF WHICH BORON-10 ((10)B) AND GADOLINIUM-157 ((157)GD) HAVE BEEN SHOWN TO BE VERY PROMISING. (10)B HAS A HIGH CROSS SECTION FOR THERMAL NEUTRONS AND A VERY VERSATILE CHEMISTRY. (157)GD HAS THE HIGHEST CROSS SECTION FOR THERMAL NEUTRONS AND, BEING PARAMAGNETIC, IS GOOD FOR MAGNETIC RESONANCE IMAGING. A COMBINATION OF THESE TWO NUCLEI IN A SINGLE ENTITY SHOULD PROVIDE A SINGLE, MORE CONVENIENT WAY TO DIAGNOSE AND TREAT TUMORS. PHASE I RESEARCH FOCUSES ON THE SYNTHESIS OF A MOLECULE CONTAINING BOTH (10)B AND (157)GD AND ON EVALUATING ITS STABILITY, TOXICITY (LD50), AND IN-VITRO EFFICACY. PHASE II RESEARCH WILL BE CONCERNED WITH THE EVALUATION OF IN-VIVO EFFICACY, STRUCTURE-ACTIVITY RELATIONSHIP STUDIES TO OPTIMIZE EFFICACY AND DETERMINE THE PHARMACOKINETICS, TISSUE DISTRIBUTION, AND TOXICITY (SAFETY) OF LEAD COMPOUND(S).

Principal Investigator:

Dr. Bernard F. Spielvogel
0

Business Contact:

Mr. Todd Bishop
9198322044
Small Business Information at Submission:

Boron Biologicals Inc.
533 Pylon Dr Raleigh, NC 27606

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No